克拉屈滨、伊达比星和阿糖胞苷(CLIA)联合或不联合索拉非尼作为急性髓系白血病初始治疗的II期研究
本研究在≤65岁适合强化治疗的新诊断AML患者中评估CLIA方案,FLT3-ITD突变者加用索拉非尼。80例入组,初治AML的CR+CRi率为83%(54/65),ts-AML为27%;FLT3-ITD突变者CR+CRi率95%,MRD阴性率81%。中位随访76个月,初治AML的2年和4年OS分别为57%和50%,ts-AML分别为20%和13%;CLIA+索拉非尼组2年和5年OS分别为63%和59%。
要点
- CLIA方案在年轻适合强化治疗的初治AML中CR+CRi率83%(54/65),ts-AML仅27%。
- FLT3-ITD突变AML加用索拉非尼后CR+CRi率95%,MRD阴性率81%,2年和5年OS分别为63%和59%。
- 初治AML的2年和4年OS分别为57%和50%,ts-AML分别为20%和13%。
核心结论
- CLIA方案在年轻、适合强化治疗的初治AML患者中安全有效,但ts-AML患者结局较差。
- FLT3-ITD突变AML在CLIA基础上加用索拉非尼获得高比例持久缓解和优异长期生存。
研究设计与样本
- II期研究,纳入≤65岁适合强化治疗的新诊断AML患者,共80例(初治AML 65例,既往治疗MDS继发AML即ts-AML 15例),中位年龄55岁(范围21-65)。
- CLIA方案:克拉屈滨5 mg/m2静脉第1-5天,阿糖胞苷1 g/m2第1-5天,伊达比星10 mg/m2第1-3天;FLT3-ITD突变者在CLIA基础上加用索拉非尼。
主要发现
- 初治AML组CR+CRi率为83%(54/65),ts-AML组为27%;两组应答者中MRD阴性率分别为74%和75%。
- FLT3-ITD突变接受CLIA+索拉非尼者CR+CRi率95%,MRD阴性率81%。
- 中位随访76个月,初治AML的2年和4年OS分别为57%和50%,ts-AML分别为20%和13%。
- CLIA+索拉非尼组2年和5年OS分别为63%和59%。
- 最常见≥3级不良事件为感染/发热、胆红素升高、皮疹和恶心。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The addition of cladribine, or sorafenib to standard chemotherapy have each demonstrated improved survival in patients with newly-diagnosed acute myeloid leukemia (AML). We studied the combination of cladribine, idarubicin, and intermediate-dose cytarabine (CLIA) in patients ≤65 years of age with newly diagnosed AML, fit to receive intensive therapy. Cladribine (5 mg/m2) IV was administered on days (D)1-5, cytarabine (1 g/m2) on D1-5, and idarubicin (10 mg/m2) on D1-3. Sorafenib was added to the CLIA backbone for patients with FLT3-ITD mutated AML. 80 patients were enrolled: 65 with newly diagnosed AML and 15 with AML arising from previously treated MDS (ts-AML). The median age was 55 years (range, 21-65). CR + CRi was 83% (54/65) and 27% in the untreated and ts-AML cohorts, respectively; 74% and 75% of responding patients, respectively, had undetectable measurable residual disease (MRD). Among patients with FLT3-ITD mutated AML receiving CLIA+sorafenib, the CR + CRi rate was 95%, with 81% negative for MRD. With a median follow-up of 76 months, the 2- and 4-year OS of 57% and 50% compared to 20%, and 13% for ts-AML, respectively. Patients treated with CLIA+sorafenib had 2- and 5-year OS rates of 63% and 59%, respectively. The most common Grade ≥3 adverse events were infection/fever, elevated bilirubin, rash, and nausea. CLIA was safe and effective in young, fit patients with newly diagnosed AML with inferior outcomes among patients with ts-AML. The addition of sorafenib to CLIA in FLT3-ITD mutated AML resulted in high rates of durable remission and excellent long-term survival.
引用
- Kadia TM, Ravandi F, Molica M, et al. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol. 2023. PMID: 37635400. doi:10.1002/ajh.27054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。